Mirus Bio 20 year anniversary

View our 20-year transfection timeline at Mirus Transfectopedia®.

The Transfection Experts

From basic research to product development, Mirus Bio scientists utilize their expertise in nucleic acid chemistry, cellular and molecular biology to establish innovative technologies and products for use in life science research. Over a decade ago, our first products reflected advancements achieved in our non-viral gene therapy research. Since then, our scientists have made significant contributions providing new and better tools for a variety of research applications in the life sciences.

Our technologies and expertise precipitated the acquisition of Mirus Bio Corporation's therapeutic division by Hoffman-La Roche in 2008. However, Mirus Bio's biological research products division remains as a stand-alone entity called Mirus Bio LLC.

History

Internationally recognized gene therapy specialist, Jon Wolff, along with his colleagues James Hagstrom and Vladimir Budker founded the company in 1995, based on research they performed at the University of Wisconsin-Madison.

Mirus was founded on the principle that non-viral (i.e. plasmid DNA based) methods offer distinct advantages over viral methods of gene transfer. Following this path, Mirus has pioneered the development of a wide range of non-viral delivery technologies using proteins, polymers, and lipids in conjunction with novel chemistries that provide unique nucleic acid delivery capabilities.

Mirus is a recognized leader in developing innovative nucleic acid research reagents, distinguished by its many accomplishments:

  • First to develop an siRNA transfection reagent
  • Pioneered development of high efficiency/low toxicity transfection formulations
  • First to market a single step nucleic acid labeling technology
  • Unique technology to label native, biologically relevant short RNA species such as microRNA
Mirus’ TransIT® Reagents are unique lipid and polymer formulations that achieve superior delivery efficiency of pDNA and siRNA with minimal cytotoxic effects. They have been optimized for in vitro delivery in a variety of mammalian cells as well as for in vivo delivery in small animals. The Ingenio® Electroporation Solution allows researchers to deliver nucleic acids to cells that are resistant to transfection.

The company’s Label IT® Kits employ proprietary chemistry to covalently attach labeling molecules to DNA and RNA. This simple one-step process is faster and more robust than traditional multi-step enzymatic labeling, and can be used for intracellular tracking, chromosome analysis, and microarray labeling.

Research Products

  • TransIT® Transfection Reagents
    - pDNA and DNA vectors
    - siRNA, mRNA and viral RNA
  • Ingenio® Electroporation Solutions
    - DNA
  • Label IT® Labeling Reagents
    - DNA & RNA, including miRNA

Focus

Experts in nucleic acid chemistry and delivery

Technology Portfolio

Transfection Reagents
Electroporation Reagents
Synthetic siRNA Delivery
Labeling Reagents

Ownership

Privately held
Close